Zobrazeno 1 - 2 of 2 pro vyhledávání: '"José L. de Andrade Neto"'
1
Akademický článek
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Autor: David A Cooper, Damien V Cordery, Roberto Zajdenverg, Kiat Ruxrungtham, Keikawus Arastéh, Frank Bergmann, José L de Andrade Neto, Joseph Scherer, Ricardo L Chaves, Patrick Robinson, study team
Publikováno v: PLoS ONE, Vol 11, Iss 1, p e0144917 (2016)
Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. Trial 1182.33, an open-label, randomized trial, compared tw
Externí odkaz: https://doaj.org/article/3e5afe97a73d41bda4ee859fcfc3cee1
Zobrazit plný text záznamu
2
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial
Autor: Patrick A. Robinson, Damien V. Cordery, Frank Bergmann, Joseph Scherer, Roberto Zajdenverg, José L. de Andrade Neto, Keikawus Arastéh, David A. Cooper, Kiat Ruxrungtham, Ricardo L. Chaves, study team
Publikováno v: PLoS ONE, Vol 11, Iss 1, p e0144917 (2016)
PLoS ONE
Ritonavir-boosted tipranavir (TPV/r) was evaluated as initial therapy in treatment-naïve HIV-1-infected patients because of its potency, unique resistance profile, and high genetic barrier. Trial 1182.33, an open-label, randomized trial, compared tw
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2678fd306f88a0c1ebcb248f532b3015
https://doi.org/10.1371/journal.pone.0144917
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje